Comparing Fever Control by External Cooling Versus Fever Respect in Mechanically Ventilated Patients with Septic Shock
Led by Centre Hospitalier Intercommunal Creteil · Updated on 2026-09-21
820
Participants Needed
33
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the best way to manage fever in patients with septic shock who require mechanical ventilation and sedation. Septic shock is a severe condition with high mortality, often linked to infections like pneumonia. Fever can increase oxygen use and inflammation, potentially worsening organ failure, but may also slow bacterial and viral growth. Previous pilot studies showed that controlling fever with external cooling improved shock resolution and organ function, though effects on longer-term survival remain unclear. This trial compares two fever management strategies to see which better reduces mortality at 60 days.
Participants will be randomly assigned to one of two groups one will receive fever control by external cooling to maintain normal body temperature for 48 hours, and the other will have their fever respected without antipyretic therapy. The study uses covariate-adaptive randomization and includes a subgroup with acute respiratory distress syndrome ARDS. An independent safety committee will monitor serious adverse events, and interim analyses may adjust enrollment based on results.
Throughout the study, participants will be monitored for mortality at 60 days as the primary outcome. Secondary measures include organ function scores, days free from ventilators, kidney therapy, vasopressors, and monitoring for complications like shivering, seizures, hypothermia, arrhythmias, infections, ARDS development, and acute kidney injury. The trial spans several years, with detailed assessments during and after treatment to evaluate the impact of fever management strategies on patient outcomes.
CONDITIONS
Brief Title
Fever Control Using External Cooling in Mechanically Ventilated Patients With Septic Shock
Research Team
F
Frédérique SCHORTGEN, MD
C
Camille JUNG, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Documented or suspected infection, either community or hospital acquired
Septic shock defined by need for vasopressor and lactate > 2 mmol/l despite adequate fluid resuscitation
Patients under invasive mechanical ventilation
Body core temperature > 38.3°C
Receiving intravenous sedation or opioids
Ongoing antimicrobial treatment or intervention to control infection source
Attending physician confirms no substantial risk participating
Informed consent given by next of kin or designated person before inclusion, or emergency inclusion procedure
You will not qualify if you...
Cardiac arrest within previous 7 days
Acute brain injury within previous 7 days
Extensive burns or epidermal necrolysis
Younger than 18 years old
Body core temperature > 41°C
Under legal guardianship
No affiliation with the French health-care system
Pregnancy
Participation in another interventional study with mortality as primary endpoint
Investigator's decision not to resuscitate
Already recruited in this trial
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 48 hours
Participants are randomly assigned to either fever control by external cooling to maintain normal body temperature for 48 hours or to have their fever respected without cooling treatment.
Continuous monitoring during treatment period
Follow-up
Duration - 60 days
Participants are monitored for outcomes including mortality, organ function, and complications up to 60 days after randomization.
Periodic assessments up to day 60
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Fludrocortisone Dosing Trial for Critically Ill Adults with Septic Shock Receiving Hydrocortisone Evaluating Survival and Recovery
Pilot Study of Adding Fludrocortisone to Hydrocortisone Treatment in Adults with Septic Shock to Assess Feasibility of a Large International Trial
Comparing Adrenaline and Dopamine to Treat Fluid Refractory Septic Shock in Children Aged 1 Month to 12 Years
Study of Albumin and Crystalloid Fluids to Improve Survival in Adults with Septic Shock
Study of Aminoglycoside Antibiotics with Continuous Renal Replacement Therapy in Adults With Sepsis or Septic Shock and Kidney Impairment
ARTISTRY Registry Study for ARTICE4 Therapy Use in Adults with Sepsis and Septic Shock
Comparing Hour-1 and 3-Hour Sepsis Treatment Bundles to Improve Survival and Respiratory Outcomes in Adults with Sepsis in the Emergency Department
Studying Muscle Function via L3 CT Scans and Its Link to 3-Month Survival After ICU Stay for Septic Shock Patients
Evaluation of Left and Right Atrial Strain Measurements in Adults with Septic Shock Using Echocardiographic Software
Study on Initial High-Dose Beta-Lactam Antibiotics to Improve Outcomes in Critically Ill Adults with Sepsis